J 2020

Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology

VAN BEEK, Nina, Stine KRÜGE, Tarek FUHRMANN, Susanne LEMCKE, Stephanie GOLETZ et. al.

Basic information

Original name

Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology

Authors

VAN BEEK, Nina, Stine KRÜGE, Tarek FUHRMANN, Susanne LEMCKE, Stephanie GOLETZ, Christian PROBST, Lars KOMOROWSKI, Giovanni DI ZENZO, Marian DMOCHOWSKI, Kossara DRENOVSKA, Michael HORN, Hana JEDLIČKOVÁ (203 Czech Republic, belonging to the institution), Cezary KOWALEWSKI, Ljiljana MEDENICA, Dedee MURRELL, Aikaterini PATSATSI, Shamir GELLER, Soner UZUN, Snejina VASSILEVA, Xuejun ZHU, Kai FECHNER, Detlef ZILLIKENS, Winfried STÖCKER, Enno SCHMIDT (guarantor) and Kristin RENTZSCH

Edition

Journal of the American Academy of Dermatology, New York, MOSBY-ELSEVIER, 2020, 0190-9622

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30216 Dermatology and venereal diseases

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 11.527

RIV identification code

RIV/00216224:14110/20:00116748

Organization unit

Faculty of Medicine

UT WoS

000582505200038

Keywords in English

autoimmune bullous diseases; biochip; immunofluorescence; pemphigoid; pemphigus

Tags

Tags

International impact, Reviewed
Změněno: 13/1/2021 13:57, Mgr. Tereza Miškechová

Abstract

V originále

Background: The current standard in the serologic diagnosis of autoimmune bullous diseases (AIBD) is a multistep procedure sequentially applying different assays. In contrast, the BIOCHIP Mosaic technology combines multiple substrates for parallel analysis by indirect immunofluorescence. Methods: Sera from 749 consecutive, prospectively recruited patients with direct immunofluorescence-positive AIBD from 13 international study centers were analyzed independently and blinded by using (1) a BIOCHIP Mosaic including primate esophagus, salt-split skin, rat bladder, monkey liver, monkey liver with serosa, recombinant BP180 NC16A, and gliadin GAF3X, as well as HEK293 cells expressing recombinant desmoglein 1, desmoglein 3, type VII collagen, and BP230 C-terminus and (2) the conventional multistep approach of the Department of Dermatology, University of Lubeck. Results: In 731 of 749 sera (97.6%), specific autoantibodies could be detected with the BIOCHIP Mosaic, similar to the conventional procedure (725 cases, 96.8%). The Cohen k for both serologic approaches ranged from 0.84 to 1.00. In 6.5% of sera, differences between the 2 approaches occurred and were mainly attributed to autoantigen fragments not present on the BIOCHIP Mosaic. Limitations: Laminin 332 and laminin gamma 1 are not represented on the BIOCHIP Mosaic. Conclusions: The BIOCHIP Mosaic is a standardized time- and serum-saving approach that further facilitates the serologic diagnosis of AIBD.